# Atossa Therapeutics, Inc.: financial statements, quarterly

ATOS · Nasdaq · CIK 1488039 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/atos.md) · [Financials](/companies/atos/financials.md) · [Filings](/companies/atos/filings.md) · [Insiders](/companies/atos/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atos/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [4.5](/filings/0000950170-24-124668.md) | [5.7 d](/filings/0000950170-25-044099.md) | [3.7](/filings/0000950170-25-069827.md) | [3.6](/filings/0000950170-25-106947.md) | [3.4](/filings/0001193125-25-276160.md) | [3.4 d](/filings/0001193125-26-124396.md) | [4.2](/filings/0001193125-26-213423.md) | [5.5](/filings/0001193125-26-339257.md) | [5.4](/filings/0001193125-25-276160.md) | [6.2 d](/filings/0001193125-26-124396.md) | [4.8](/filings/0001193125-26-213423.md) | [4.9](/filings/0001193125-26-339257.md) |
| Operating income | $m | [(7.5)](/filings/0000950170-24-124668.md) | [(9.0) d](/filings/0000950170-25-044099.md) | [(7.0)](/filings/0000950170-25-069827.md) | [(7.1)](/filings/0000950170-25-106947.md) | [(6.4)](/filings/0001193125-25-276160.md) | [(7.2) d](/filings/0001193125-26-124396.md) | [(7.4)](/filings/0001193125-26-213423.md) | [(9.0)](/filings/0001193125-26-339257.md) | [(9.3)](/filings/0001193125-25-276160.md) | [(11.4) d](/filings/0001193125-26-124396.md) | [(9.9)](/filings/0001193125-26-213423.md) | [(8.7)](/filings/0001193125-26-339257.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-124668.md) | [0.0 d](/filings/0000950170-25-044099.md) | [0.0](/filings/0000950170-25-069827.md) | [0.0](/filings/0000950170-25-106947.md) | [0.0](/filings/0001193125-25-276160.md) | [0.0 d](/filings/0001193125-26-124396.md) | [0.0](/filings/0001193125-26-213423.md) | [0.0](/filings/0001193125-26-339257.md) | [0.0](/filings/0001193125-25-276160.md) | [0.0 d](/filings/0001193125-26-124396.md) | [0.0](/filings/0001193125-26-213423.md) | [0.0](/filings/0001193125-26-339257.md) |
| Net income | $m | [(6.2)](/filings/0000950170-24-124668.md) | [(7.8) d](/filings/0000950170-25-044099.md) | [(5.9)](/filings/0001193125-25-276160.md) | [(6.0)](/filings/0001193125-25-276160.md) | [(7.2)](/filings/0001193125-25-276160.md) | [(6.3) d](/filings/0001193125-26-124396.md) | [(6.7)](/filings/0001193125-26-339257.md) | [(8.4)](/filings/0001193125-26-339257.md) | [(8.7)](/filings/0001193125-25-276160.md) | [(10.9) d](/filings/0001193125-26-124396.md) | [(9.6)](/filings/0001193125-26-339257.md) | [(8.5)](/filings/0001193125-26-339257.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0000950170-24-124668.md) | not reported | [(0.05)](/filings/0000950170-25-069827.md) | [(0.05)](/filings/0000950170-25-106947.md) | [(0.06)](/filings/0001193125-25-276160.md) | not reported | [(0.78)](/filings/0001193125-26-213423.md) | [(0.98)](/filings/0001193125-26-339257.md) | [(0.07)](/filings/0001193125-25-276160.md) | not reported | [(1.11)](/filings/0001193125-26-213423.md) | [(0.95)](/filings/0001193125-26-339257.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0000950170-24-124668.md) | not reported | [(0.05)](/filings/0000950170-25-069827.md) | [(0.05)](/filings/0000950170-25-106947.md) | [(0.06)](/filings/0001193125-25-276160.md) | not reported | [(0.78)](/filings/0001193125-26-213423.md) | [(0.98)](/filings/0001193125-26-339257.md) | [(0.07)](/filings/0001193125-25-276160.md) | not reported | [(1.11)](/filings/0001193125-26-213423.md) | [(0.95)](/filings/0001193125-26-339257.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.0](/filings/0000950170-24-124668.md) | [88.5](/filings/0000950170-25-044099.md) | [84.0](/filings/0000950170-25-069827.md) | [79.5](/filings/0000950170-25-106947.md) | [74.8](/filings/0001193125-25-276160.md) | [71.1](/filings/0001193125-26-124396.md) | [65.1](/filings/0001193125-26-213423.md) | [57.9](/filings/0001193125-26-339257.md) | [51.8](/filings/0001193125-25-276160.md) | [41.3](/filings/0001193125-26-339257.md) | [31.7](/filings/0001193125-26-213423.md) | [26.1](/filings/0001193125-26-339257.md) |
| Current assets | $m | [97.6](/filings/0001437749-23-031424.md) | [92.2](/filings/0000950170-25-044099.md) | [87.1](/filings/0000950170-24-058244.md) | [81.7](/filings/0000950170-24-095102.md) | [77.1](/filings/0000950170-24-124668.md) | [74.5](/filings/0001193125-26-124396.md) | [68.7](/filings/0000950170-25-069827.md) | [62.5](/filings/0000950170-25-106947.md) | [55.7](/filings/0001193125-25-276160.md) | [45.6](/filings/0001193125-26-339257.md) | [36.7](/filings/0001193125-26-213423.md) | [31.0](/filings/0001193125-26-339257.md) |
| Total assets | $m | [102](/filings/0001437749-23-031424.md) | [96.3](/filings/0000950170-25-044099.md) | [91.1](/filings/0000950170-24-058244.md) | [85.9](/filings/0000950170-24-095102.md) | [79.5](/filings/0000950170-24-124668.md) | [76.4](/filings/0001193125-26-124396.md) | [70.7](/filings/0000950170-25-069827.md) | [64.5](/filings/0000950170-25-106947.md) | [58.0](/filings/0001193125-25-276160.md) | [47.6](/filings/0001193125-26-339257.md) | [37.9](/filings/0001193125-26-213423.md) | [32.3](/filings/0001193125-26-339257.md) |
| Current liabilities | $m | [3.4](/filings/0001437749-23-031424.md) | [5.2](/filings/0000950170-25-044099.md) | [5.3](/filings/0000950170-24-058244.md) | [5.7](/filings/0000950170-24-095102.md) | [5.8](/filings/0000950170-24-124668.md) | [5.0](/filings/0001193125-26-124396.md) | [5.4](/filings/0000950170-25-069827.md) | [6.8](/filings/0000950170-25-106947.md) | [8.2](/filings/0001193125-25-276160.md) | [8.3](/filings/0001193125-26-339257.md) | [7.5](/filings/0001193125-26-213423.md) | [5.5](/filings/0001193125-26-339257.md) |
| Total liabilities | $m | [3.4](/filings/0001437749-23-031424.md) | [5.2](/filings/0000950170-25-044099.md) | [5.3](/filings/0000950170-24-058244.md) | [5.7](/filings/0000950170-24-095102.md) | [5.8](/filings/0000950170-24-124668.md) | [5.0](/filings/0001193125-26-124396.md) | [5.4](/filings/0000950170-25-069827.md) | [6.8](/filings/0000950170-25-106947.md) | [8.2](/filings/0001193125-25-276160.md) | [8.3](/filings/0001193125-26-339257.md) | [7.5](/filings/0001193125-26-213423.md) | [5.5](/filings/0001193125-26-339257.md) |
| Shareholders' equity | $m | [98.3](/filings/0000950170-24-124668.md) | [91.0](/filings/0001193125-26-124396.md) | [85.8](/filings/0001193125-25-276160.md) | [80.2](/filings/0001193125-25-276160.md) | [73.7](/filings/0001193125-25-276160.md) | [71.5](/filings/0001193125-26-339257.md) | [65.3](/filings/0001193125-26-339257.md) | [57.7](/filings/0001193125-26-339257.md) | [49.8](/filings/0001193125-25-276160.md) | [39.4](/filings/0001193125-26-339257.md) | [30.5](/filings/0001193125-26-339257.md) | [26.8](/filings/0001193125-26-339257.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.9) d](/filings/0000950170-24-124668.md) | [(5.6) d](/filings/0000950170-25-044099.md) | [(4.7)](/filings/0000950170-25-069827.md) | [(4.5) d](/filings/0000950170-25-106947.md) | [(4.8) d](/filings/0001193125-25-276160.md) | [(7.1) d](/filings/0001193125-26-124396.md) | [(6.0)](/filings/0001193125-26-213423.md) | [(7.3) d](/filings/0001193125-26-339257.md) | [(6.0) d](/filings/0001193125-25-276160.md) | [(10.5) d](/filings/0001193125-26-124396.md) | [(9.6)](/filings/0001193125-26-213423.md) | [(9.6) d](/filings/0001193125-26-339257.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-124668.md) | [0.0 d](/filings/0000950170-25-044099.md) | [0.0](/filings/0000950170-25-069827.md) | [0.0 d](/filings/0000950170-25-106947.md) | [0.0 d](/filings/0001193125-25-276160.md) | [0.0 d](/filings/0001193125-26-124396.md) | [0.0](/filings/0001193125-26-213423.md) | [0.0 d](/filings/0001193125-26-339257.md) | [0.0 d](/filings/0001193125-25-276160.md) | [0.0 d](/filings/0001193125-26-124396.md) | [0.0](/filings/0001193125-26-213423.md) | [0.0 d](/filings/0001193125-26-339257.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0000950170-25-044099.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [127](/filings/0000950170-24-058244.md) | [127](/filings/0000950170-24-095102.md) | [126](/filings/0000950170-24-124668.md) | [125](/filings/0000950170-25-069827.md) | [126](/filings/0000950170-25-106947.md) | [126](/filings/0001193125-25-276160.md) | [8.6](/filings/0001193125-26-213423.md) | [8.6](/filings/0001193125-26-339257.md) | [129](/filings/0001193125-25-276160.md) | [8.6](/filings/0001193125-26-213423.md) | [8.9](/filings/0001193125-26-339257.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,979,298 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-339257.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.